证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

立方制药8月20日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 中信证券股份有限公司北京安外大街证券营业部 | 4351.82 | 1.14 | | 买二 | 机构专用 | 2605.43 | 1729.21 | | 买三 | 机构专用 | 2128.21 | 1032.56 | | 买四 | 中国银河证券股份有限公司北京远大路证券营业部 | 1636.29 | 0.00 | | 买五 | 兴业证券股份有限公司晋江泉安路证券营业部 | 1606.79 | 0.00 | | 卖一 | 机构专用 | 0.00 | 2720.64 | | 卖二 | 机构专用 | 0.00 | 2574.93 | | 卖三 | 开源证券股份有限公司西安西大街证券营业部 | 0.00 | 2257.24 | | 卖四 | 机构专用 | 693.71 | 1856.33 | | 卖五 | 中信证券股份有限公司上海静安区山西北路证券营业 | 25.33 | 1832.38 | | | 部 | | | 证券时报·数据宝统计显示 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：003020 证券简称：立方制药 公告编号：2025-061 合肥立方制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动的情况介绍 合肥立方制药股份有限公司（以下称"公司"）（股票简称：立方制药，股票代码：003020）股票于2025 年8月15日、2025年8月18日、2025年8月19日连续三个交易日收盘价格涨幅偏离值累计超过20%，根据 《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动情形。 二、公司关注并核实情况的说明 针对公司股票交易异常波动，公司董事会对公司、控股股东和实际控制人就相关事项进行了核实，有关 情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的未公开重大信 息； 1、经自查，公司不存在违反信息公平披露的情形。 2、截至本公告日，根据《深圳证券交易所股票上市规则》等相关规定，公司不存在需披露2025年半年 度业绩预告的情形 ...

Core Viewpoint - The stock of Lifan Pharmaceutical experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days [1] Summary by Relevant Sections - **Stock Performance** The company's stock closed with a price increase of over 20% on August 15, 18, and 19, 2025, indicating significant market activity [1] - **Company Operations** The company confirmed that its recent operational status is normal, and there have been no significant changes in the internal or external business environment [1] - **Disclosure of Information** Lifan Pharmaceutical stated that there are no corrections or supplements needed for previously disclosed information, and there are no undisclosed significant matters related to the company by the company, its controlling shareholders, or actual controllers [1]

证券代码：003020 证券简称：立方制药 公告编号：2025-061 合肥立方制药股份有限公司 股票交易异常波动公告 三、不存在应披露而未披露信息的说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 合肥立方制药股份有限公司（以下称"公司"）（股票简称：立方制药，股票代 码：003020）股票于 2025 年 8 月 15 日、2025 年 8 月 18 日、2025 年 8 月 19 日连续 三个交易日收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规则》 的相关规定，属于股票交易异常波动情形。 二、公司关注并核实情况的说明 针对公司股票交易异常波动，公司董事会对公司、控股股东和实际控制人就相 关事项进行了核实，有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3、公司近期经营情况正常，内外部经营环境未发生重大变化； 4、公司、控股股东及实际控制人不存在关于公司的应披露而未披露的重大事项， 或处于 ...

Group 1 - The core viewpoint of the articles highlights a significant surge in the innovative drug sector, with companies like Shenlian Bio and Boji Pharmaceutical reaching their historical highs, indicating a shift from "follower" to "leader" in China's innovative drug industry [1] - The current phase of China's innovative drug industry is identified as the 3.0 era, with expectations for 2025 to be a pivotal year for the overseas explosion of Chinese innovative drugs, with many products projected to exceed peak sales of $3 billion to $5 billion [1] - The investment opportunities in the innovative drug sector this year are anticipated to be greater than those in 2020-2021, driven by ongoing advancements and record-breaking licensing transactions [1] Group 2 - The National Medical Insurance Administration has recently published the preliminary list of drugs for the 2025 National Medical Insurance Drug Directory and commercial insurance innovative drug directory, with several cancer drugs and new drugs in chronic disease areas passing initial reviews [2] - The innovative drugs set to be included in the medical insurance and commercial insurance directories are mostly at a low base stage, suggesting potential for rapid growth as policy support continues to be released [2] - As the mid-year reporting season approaches, there are recommendations for investment opportunities based on the performance of companies in the second half of the year [2]

Company Performance - Lifan Pharmaceutical's stock price reached a historical high, increasing by 6.45% to 35.81 yuan, with a trading volume of 2.0682 million shares and a transaction value of 73.2369 million yuan, resulting in a turnover rate of 1.50% [2] - The company's latest A-share total market capitalization is 6.81 billion yuan, with a circulating market capitalization of 4.932 billion yuan [2] Industry Overview - The pharmaceutical and biotechnology industry has an overall increase of 0.50%, with 300 stocks rising, including notable gainers such as Furuide Co., Norsland, and Jimin Health, which saw increases of 18.46%, 10.98%, and 10.00% respectively [2] - Conversely, 176 stocks in the industry experienced declines, with the largest drops seen in Guangyuyuan, Haochen Medical, and Meihao Medical, which fell by 5.19%, 4.01%, and 3.45% respectively [2] Financial Results - In the first quarter, the company reported a total revenue of 360 million yuan, reflecting a year-on-year growth of 7.98% [2] - The net profit for the same period was 38.2503 million yuan, representing a year-on-year increase of 25.94%, with basic earnings per share of 0.2000 yuan and a weighted average return on equity of 2.18% [2]

Market Overview - The A-share market continued to rebound, with the Shanghai Composite Index rising by 0.44%, the Shenzhen Component Index by 0.57%, and the ChiNext Index by 1.04% as of 9:45 AM on August 19 [1] - The pharmaceutical sector showed strong performance, particularly in innovative drugs, with Ji Min Health hitting the daily limit [1] - AI hardware stocks like New Yisheng and Zhongji Xuchuang reached historical highs, while sectors such as film, media, military, banking, oil and gas, and wind power experienced declines [1] Key Sectors Innovative Drug Sector - The innovative drug sector saw significant gains, with Ji Min Health and Kangyuan Pharmaceutical hitting the daily limit, and other companies like Nuo Si Lan De and Li Fang Pharmaceutical also rising [2] - CITIC Securities reports a favorable policy environment for innovative drugs starting from 2025, recommending investments in innovation-driven and internationalization strategies, particularly in the innovative drug field [2] CPO Concept - CPO concept stocks maintained strong performance, with New Yisheng and Zhongji Xuchuang reaching historical highs, and companies like Jianqiao Technology and Tengjing Technology also seeing gains [3] - CITIC Jiantou Securities highlights a shift in AI training network architecture, leading to increased demand for optical modules, with 800G optical modules expected to see significant growth starting in 2023 [3] Institutional Insights Shenwan Hongyuan - Shenwan Hongyuan believes the short-term bull market atmosphere will continue to dominate, with a focus on securities, insurance, military, and rare earth sectors before early September [4] - The firm emphasizes the importance of sectors with scarce overseas computing power and suggests a price alliance in high market share manufacturing segments [4] Huatai Securities - Huatai Securities suggests that the market may have entered the mid-stage of a bull market, characterized by structural features and rapid sector rotation [5] - The firm notes that the current slow bull market may extend the upward cycle, with a need for increased market signals to attract more external funds [5] Dongfang Securities - Dongfang Securities anticipates no major adjustment risks for stock indices in August, with a "local advance, multi-point bloom" characteristic in the current market [6] - The firm advises caution against potential pullbacks and emphasizes the importance of "high-low switching" in the event of market adjustments, recommending focus on technology autonomy, innovative drugs, military, and robotics sectors [6]

Company Overview - Hefei Lifang Pharmaceutical Co., Ltd. was established in 2002 and is located in Hefei City, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 1,901.82182 million RMB and a paid-in capital of 660 million RMB [1] Investment and Intellectual Property - Hefei Lifang Pharmaceutical has invested in 11 companies and participated in 5,000 bidding projects [1] - The company holds 89 trademark registrations and 88 patent registrations, along with 597 administrative licenses [1] Shareholder Information - Major shareholders include Ji Junqiu with 67.41% ownership, Deng Xiaojun with 10%, Gao Meihua with 5.34%, Li Xiaochang with 4.64%, and Cai Ying with 2% [1] Regulatory Communication - The company has applied for a "Type III meeting" with the CDE, which is currently in process, and such meetings are typically held within 75 days after the application [1]

证券日报网讯 8月12日晚间，立方制药发布公告称，公司第五届董事会第二十二次会议审议通过了《关 于修订〈公司章程〉并办理工商登记的议案》等多项议案。 （文章来源：证券日报） ...